Showing results (281-290 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 7, 2018
The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancerMei Tang, Qiuli Liu, Leyuan Zhou, et al.
Investigational New Drugs|June 12, 2019
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutationTakahisa Kawamura, Hirotsugu Kenmotsu, Haruki Kobayashi, et al.
Investigational New Drugs|June 23, 2019
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasmsXing Hao, Wen Xing, Jiajia Yuan, et al.
Investigational New Drugs|September 12, 2018
Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptorYuan Lu, Ang Li, Xiaofeng Lai, et al.
Investigational New Drugs|June 30, 2018
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaintsSarah E Stump, Young E Whang, Daniel J Crona
Investigational New Drugs|May 1, 2019
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancerVadim S Koshkin, Maria C Mir, Pedro Barata, et al.
Investigational New Drugs|January 1, 1986
Recombinant gamma interferon in advanced breast cancer: a phase II trialH B Muss, M Caponera, P J Zekan, et al.
Investigational New Drugs|March 21, 2022
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinomaSteven F Powell, Miroslaw Mazurczak, Elie G Dib, et al.
Investigational New Drugs|March 15, 2022
Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancerTing Xue, Peijia Xu, Jonathan Padelford, et al.
Investigational New Drugs|April 20, 2022
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case reportXiang Tian, Qiong Liao, Qidong Yang, et al.
Pageof 372